Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study.

Moik F, Huemer F, Doleschal B, Taghizadeh H, Reimann P, Kostmann SM, Wagner L, Abdel Hamid M, Zimmer KC, Suppé SA, Bachleitner C, Schaberl-Moser R, Amann A, Wolf D, Greil R, Jost PJ, Winder T, Rumpold H, Weiss L, Gerger A, Seeber A, Riedl JM

Open source

DOI
10.1016/j.esmoop.2026.106907
Published
2026 Apr
Container
ESMO open
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2026.106907,
  title = {Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study.},
  author = {Moik F and Huemer F and Doleschal B and Taghizadeh H and Reimann P and Kostmann SM and Wagner L and Abdel Hamid M and Zimmer KC and Suppé SA and Bachleitner C and Schaberl-Moser R and Amann A and Wolf D and Greil R and Jost PJ and Winder T and Rumpold H and Weiss L and Gerger A and Seeber A and Riedl JM},
  year = {2026},
  journal = {ESMO open},
  doi = {10.1016/j.esmoop.2026.106907},
  url = {https://doi.org/10.1016/j.esmoop.2026.106907}
}

RIS

TY  - JOUR
TI  - Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study.
AU  - Moik F
AU  - Huemer F
AU  - Doleschal B
AU  - Taghizadeh H
AU  - Reimann P
AU  - Kostmann SM
AU  - Wagner L
AU  - Abdel Hamid M
AU  - Zimmer KC
AU  - Suppé SA
AU  - Bachleitner C
AU  - Schaberl-Moser R
AU  - Amann A
AU  - Wolf D
AU  - Greil R
AU  - Jost PJ
AU  - Winder T
AU  - Rumpold H
AU  - Weiss L
AU  - Gerger A
AU  - Seeber A
AU  - Riedl JM
PY  - 2026
JO  - ESMO open
DO  - 10.1016/j.esmoop.2026.106907
UR  - https://doi.org/10.1016/j.esmoop.2026.106907
ER  - 

APA

F, M., F, H., B, D., H, T., P, R., SM, K., L, W., M, A. H., KC, Z., SA, S., C, B., R, S., A, A., D, W., R, G., PJ, J., T, W., H, R., L, W., A, G., A, S., & JM, R. (2026). Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study.. ESMO open. https://doi.org/10.1016/j.esmoop.2026.106907

Source records